Show simple item record

dc.contributor.authorKong, Jiming
dc.contributor.authorXu, Zuoshang
dc.date2022-08-11T08:09:31.000
dc.date.accessioned2022-08-23T16:34:20Z
dc.date.available2022-08-23T16:34:20Z
dc.date.issued1998-05-09
dc.date.submitted2009-03-10
dc.identifier.citationJ Neurosci. 1998 May 1;18(9):3241-50.
dc.identifier.issn0270-6474 (Print)
dc.identifier.pmid9547233
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38308
dc.description.abstractAmyotrophic lateral sclerosis (ALS) involves motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. Mutations in Cu,Zn superoxide dismutase (SOD1) are one cause of the disease. Mice transgenic for mutated SOD1 develop symptoms and pathology similar to those in human ALS. To understand the disease mechanism, we developed a simple behavioral assay for disease progression in mice. Using this assay, we defined four stages of the disease in mice expressing G93A mutant SOD1. By studying mice with defined disease stages, we tied several pathological features into a coherent sequence of events leading to motor neuron death. We show that onset of the disease involves a sharp decline of muscle strength and a transient explosive increase in vacuoles derived from degenerating mitochondria, but little motor neuron death. Most motor neurons do not die until the terminal stage, approximately 9 weeks after disease onset. These results indicate that mutant SOD1 toxicity is mediated by damage to mitochondria in motor neurons, and this damage triggers the functional decline of motor neurons and the clinical onset of ALS. The absence of massive motor neuron death at the early stages of the disease indicates that the majority of motor neurons could be rescued after clinical diagnosis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=9547233&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAmyotrophic Lateral Sclerosis
dc.subjectAnimals
dc.subjectAxons
dc.subjectDisease Progression
dc.subjectGene Expression Regulation, Enzymologic
dc.subjectHumans
dc.subjectMice
dc.subjectMice, Transgenic
dc.subjectMitochondrial Encephalomyopathies
dc.subjectMotor Neurons
dc.subjectMutation
dc.subjectNerve Degeneration
dc.subjectSpinal Cord
dc.subjectSuperoxide Dismutase
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleMassive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1
dc.typeJournal Article
dc.source.journaltitleThe Journal of neuroscience : the official journal of the Society for Neuroscience
dc.source.volume18
dc.source.issue9
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2177&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1178
dc.identifier.contextkey770156
refterms.dateFOA2022-08-23T16:34:20Z
html.description.abstract<p>Amyotrophic lateral sclerosis (ALS) involves motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. Mutations in Cu,Zn superoxide dismutase (SOD1) are one cause of the disease. Mice transgenic for mutated SOD1 develop symptoms and pathology similar to those in human ALS. To understand the disease mechanism, we developed a simple behavioral assay for disease progression in mice. Using this assay, we defined four stages of the disease in mice expressing G93A mutant SOD1. By studying mice with defined disease stages, we tied several pathological features into a coherent sequence of events leading to motor neuron death. We show that onset of the disease involves a sharp decline of muscle strength and a transient explosive increase in vacuoles derived from degenerating mitochondria, but little motor neuron death. Most motor neurons do not die until the terminal stage, approximately 9 weeks after disease onset. These results indicate that mutant SOD1 toxicity is mediated by damage to mitochondria in motor neurons, and this damage triggers the functional decline of motor neurons and the clinical onset of ALS. The absence of massive motor neuron death at the early stages of the disease indicates that the majority of motor neurons could be rescued after clinical diagnosis.</p>
dc.identifier.submissionpathoapubs/1178
dc.contributor.departmentDepartment of Cell Biology
dc.contributor.departmentDepartment of Pharmacology and Molecular Toxicology
dc.source.pages3241-50


Files in this item

Thumbnail
Name:
9547233.pdf
Size:
1015.Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record